Q4 2024 · 13F-HR
BVF INC/ILholdings as filed
Filed 2025-02-14 · accession 0000921895-25-000463
$2.95B
Reported value
53
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $1.07B | 36.2% | 19,751,284 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $207.7M | 7.04% | 5,161,801 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $182.9M | 6.20% | 4,181,179 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $117.4M | 3.98% | 1,388,064 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $115.6M | 3.92% | 2,796,513 | Common | SHARED |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $95.5M | 3.24% | 3,633,743 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $73.3M | 2.49% | 1,900,015 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $72.8M | 2.47% | 10,400,158 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $70.0M | 2.37% | 5,750,683 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $63.1M | 2.14% | 4,308,935 | Common | SHARED |
| 81734D104 | SEPN | SEPTERNA INC | $56.2M | 1.90% | 2,452,024 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $54.8M | 1.86% | 3,944,194 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $52.7M | 1.79% | 19,522,436 | Common | SHARED |
| 98401F105 | XNCR | XENCOR INC | $52.6M | 1.78% | 2,288,760 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $48.0M | 1.63% | 1,771,417 | Common | SHARED |
| 15102K100 | CELC | CELCUITY INC | $45.4M | 1.54% | 3,466,000 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $43.2M | 1.46% | 1,569,422 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $38.9M | 1.32% | 6,904,050 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $35.9M | 1.22% | 7,000,000 | Common | SHARED |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $35.3M | 1.20% | 1,073,755 | Common | SHARED |
| 282559103 | ETNBGBP | 89BIO INC | $33.9M | 1.15% | 4,333,885 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $33.3M | 1.13% | 5,715,893 | Common | SHARED |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $29.4M | 1.00% | 1,092,796 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $25.9M | 0.88% | 6,293,282 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $25.0M | 0.85% | 5,302,000 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $24.4M | 0.83% | 2,372,933 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $22.4M | 0.76% | 2,567,469 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $20.0M | 0.68% | 16,552,417 | Common | SHARED |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $19.2M | 0.65% | 2,764,471 | Common | SHARED |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $17.9M | 0.61% | 2,325,000 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $15.7M | 0.53% | 8,748,629 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $14.9M | 0.50% | 2,670,642 | Common | SHARED |
| 75382E109 | — | RAPT THERAPEUTICS INC | $14.6M | 0.49% | 9,237,556 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $14.0M | 0.47% | 2,106,037 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $13.5M | 0.46% | 10,333,600 | Common | SHARED |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $13.5M | 0.46% | 594,282 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $10.9M | 0.37% | 2,100,468 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $9.1M | 0.31% | 2,989,474 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $8.9M | 0.30% | 8,902,972 | Common | SHARED |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $8.4M | 0.28% | 696,555 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $7.7M | 0.26% | 1,036,679 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $6.6M | 0.22% | 4,006,564 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $6.5M | 0.22% | 1,353,968 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $5.4M | 0.18% | 5,228,461 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $3.6M | 0.12% | 3,853,818 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $3.5M | 0.12% | 917,826 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $3.1M | 0.10% | 1,813,633 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $2.4M | 0.08% | 9,544,262 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $2.1M | 0.07% | 339,549 | Common | SHARED |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.7M | 0.06% | 2,966,836 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $1.5M | 0.05% | 686,040 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $803,686 | 0.03% | 945,402 | Common | SHARED |
| H57830137 | — | NLS PHARMACEUTICS LTD | $303,156 | 0.01% | 143,676 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.